Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin-Reference-Cited by-同舟云学术

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

Published:2012-06-29 Issue:11 Volume:14 Page:990-999
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Ljunggren Ö.¹,Bolinder J.²,Johansson L.,Wilding J.³,Langkilde A. M.⁴,Sjöström C. D.⁴,Sugg J.⁵,Parikh S.⁵

Affiliation:

1. Osteoporosis Research Unit, Department of Medical Sciences; Uppsala University; Uppsala; Sweden

2. Department of Endocrinology, Metabolism and Diabetes; Karolinska University Hospital Huddinge, Karolinska Institute; Stockholm; Sweden

3. Department of Obesity & Endocrinology; University of Liverpool; Liverpool; UK

4. AstraZeneca; Mölndal; Sweden

5. AstraZeneca; Wilmington; DE; USA

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2012.01630.x/fullpdf

Reference33 articles.

1. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes;Meng;J Med Chem,2008

2. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial;Ferrannini;Diabetes Care,2010

3. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial;Bailey;Lancet,2010

4. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial;Nauck;Diabetes Care,2011

5. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, double-blind, placebo-controlled trial;Strojek;Diabetes Obes Metab,2011

Cited by 190 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interrelationships among metabolic syndrome, bone-derived cytokines, and the most common metabolic syndrome-related diseases negatively affecting bone quality;Diabetology & Metabolic Syndrome;2024-09-06

2. Bone Fragility in Diabetes and its Management: A Narrative Review;Drugs;2024-08-05

3. Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis;International Journal of Molecular Sciences;2024-07-22

4. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression;Expert Opinion on Drug Safety;2024-07-08

5. Potential Metabolic Pathways Involved in Osteoporosis and Evaluation of Fracture Risk in Individuals with Diabetes;BioMed Research International;2024-05-23